

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Sherif F. Nagueh, Chair, MD, FASE,¹ Otto A. Smiseth, Co-Chair, MD, PhD,² Christopher P. Appleton, MD,¹ Benjamin F. Byrd, III, MD, FASE,¹ Hisham Dokainish, MD, FASE,¹ Thor Edvardsen, MD, PhD,² Frank A. Flachskampf, MD, PhD, FESC,² Thierry C. Gillebert, MD, PhD, FESC,² Allan L. Klein, MD, FASE,¹ Patrizio Lancellotti, MD, PhD, FESC,² Paolo Marino, MD, FESC,² Jae K. Oh, MD,¹ Bogdan Alexandru Popescu, MD, PhD, FESC, FASE,² and Alan D. Waggoner, MHS, RDCS¹, *Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri*

(J Am Soc Echocardiogr 2016;29:277-314.)

Keywords: Diastole, Echocardiography, Doppler, Heart failure

TABLE OF CONTENTS

I. General Principles for Echocardiographic Assessment of LV Diastolic Function	278	F. Atrioventricular Block and Pacing	296
II. Diagnosis of Diastolic Dysfunction in the Presence of Normal LVEF	279	VI. Diastolic Stress Test	298
III. Echocardiographic Assessment of LV Filling Pressures and Diastolic Dysfunction Grade	281	A. Indications	299
IV. Conclusions on Diastolic Function in the Clinical Report	288	B. Performance	299
V. Estimation of LV Filling Pressures in Specific Cardiovascular Diseases	288	C. Interpretation	301
A. Hypertrophic Cardiomyopathy	289	D. Detection of Early Myocardial Disease and Prognosis	301
B. Restrictive Cardiomyopathy	289	VII. Novel Indices of LV Diastolic Function	301
C. Valvular Heart Disease	290	VIII. Diastolic Doppler and 2D Imaging Variables for Prognosis in Patients with HFrEF	303
D. Heart Transplantation	292	IX. Prediction of Outcomes in Patients with HFpEF	303
E. Atrial Fibrillation	295	Reviewers	306
		Notice and Disclaimer	306

From the Methodist DeBakey Heart and Vascular Center, Houston, Texas (S.F.N.); the University of Oslo, Oslo, Norway (O.A.S., T.E.); Mayo Clinic Arizona, Phoenix, Arizona (C.P.A.); Vanderbilt University School of Medicine, Nashville, Tennessee (B.F.B.); McMaster University, Hamilton, Ontario, Canada (H.D.); Uppsala University, the Institute of Medical Sciences, Uppsala, Sweden (F.A.F.); Ghent University and University Hospital, Ghent, Belgium (T.C.G.); Cleveland Clinic, Cleveland, Ohio (A.L.K.); the University of Liège Hospital, Liège, Belgium (P.L.); Università Piemonte Orientale, Novara, Italy (P.M.); Mayo Clinic, Rochester, Minnesota (J.K.O.); the University of Medicine and Pharmacy "Carol Davila," Institute of Cardiovascular Diseases, Bucharest, Romania (B.A.P.); and Washington University School of Medicine, St Louis, Missouri (A.D.W.).

The following authors reported no actual or potential conflicts of interest in relation to the document: Sherif F. Nagueh, MD, Otto Smiseth, MD, PhD, Christopher P. Appleton, MD, Benjamin F. Byrd III, MD, Hisham Dokainish, MD, Thor Edvardsen, MD, PhD, Frank A. Flachskampf, MD, PhD, Thierry C. Gillebert, MD, PhD, Allan Klein, MD, Patrizio Lancellotti, MD, PhD, Paolo Marino, MD, and Alan D. Waggoner, MHS, RDCS. The following authors reported relationships with one or more commercial interests: Jae K. Oh, MD, has served as a consultant for Medtronic and received a research grant from Toshiba. Bogdan Alexandru

Popescu, MD, PhD, has received research support from GE Healthcare and Hitachi Aloka.

Attention ASE Members:

The ASE has gone green! Visit www.aseuniversity.org to earn free continuing medical education credit through an online activity related to this article. Certificates are available for immediate access upon successful completion of the activity. Nonmembers will need to join the ASE to access this great member benefit!

Reprint requests: American Society of Echocardiography, 2100 Gateway Centre Boulevard, Suite 310, Morrisville, NC 27560 (E-mail: ase@asecho.org).

¹ Writing Committee of the American Society of Echocardiography.

² Writing Committee of the European Association of Cardiovascular Imaging.

0894-7317/\$36.00

Copyright 2016 by the American Society of Echocardiography.

<http://dx.doi.org/10.1016/j.echo.2016.01.011>

Abbreviations

2D = Two-dimensional
AR = Aortic regurgitation
ASE = American Society of Echocardiography
AV = Atrioventricular
CW = Continuous-wave
DT = Deceleration time
EACVI = European Association of Cardiovascular Imaging
EF = Ejection fraction
GLS = Global longitudinal strain
HCM = Hypertrophic cardiomyopathy
HFpEF = Heart failure with preserved ejection fraction
HFrEF = Heart failure with reduced ejection fraction
IVRT = Isovolumic relaxation time
LA = Left atrial
LAP = Left atrial pressure
LV = Left ventricular
LVEDP = Left ventricular end-diastolic pressure
LVEF = Left ventricular ejection fraction
MAC = Mitral annular calcification
MR = Mitral regurgitation
PASP = Pulmonary artery systolic pressure
PCWP = Pulmonary capillary wedge pressure
RV = Right ventricular
STE = Speckle-tracking echocardiography
TR = Tricuspid regurgitation
Vp = Flow propagation velocity

Echocardiographic assessment of left ventricular (LV) diastolic function is an integral part of the routine evaluation of patients presenting with symptoms of dyspnea or heart failure. The 2009 American Society of Echocardiography (ASE) and European Association of Cardiovascular Imaging (EACVI) guidelines for diastolic function assessment were comprehensive, including several two-dimensional (2D) and Doppler parameters to grade diastolic dysfunction and to estimate LV filling pressures.¹ Notwithstanding, the inclusion of many parameters in the guidelines was perceived to render diastolic function assessment too complex, because several readers have interpreted the guidelines as mandating all the listed parameters in the document to fall within specified values before assigning a specific grade. The primary goal of this update is to simplify the approach and thus increase the utility of the guidelines in daily clinical practice.

LV diastolic dysfunction is usually the result of impaired LV relaxation with or without reduced restoring forces (and early diastolic suction), and increased LV chamber stiffness, which increase cardiac filling pressures. Thus, when performing an echocardiographic study in patients with potential diastolic dysfunction, one should search for signs of impaired LV relaxation, reduced restoring forces and increased diastolic stiffness. More important, LV filling pressure should be estimated because elevated LV diastolic pressure in the absence of increased LV end-diastolic volume is strong evidence in favor of well-developed diastolic

reproducible, and feasible 2D and Doppler measurements from the 2009 guidelines.

Before applying the guidelines, it is essential to consider what the term *LV filling pressures* refers to. The term *LV filling pressures* can refer to mean pulmonary capillary wedge pressure (PCWP) (which is an indirect estimate of LV diastolic pressures), mean left atrial (LA) pressure (LAP), LV pre-A pressure, mean LV diastolic pressure, and LV end-diastolic pressure (LVEDP). The different LV and LA diastolic pressures mentioned above (Figure 1) have different correlates with Doppler signals. For example, in the early stages of diastolic dysfunction, LVEDP is the only abnormally elevated pressure because of a large atrial pressure wave, while mean PCWP and LAP remain normal. With tachycardia and/or increased LV afterload, mean PCWP and LAP increase which provides the basis for the diastolic stress test. Thus, it is important that one is clear on which pressure is being estimated as there are different Doppler variables that correlate with an increase in LVEDP only versus those that reflect an increase in both LAP and LVEDP. Although the current recommendations are focused on echocardiographic techniques, it should be noted that both nuclear scans and cardiac magnetic resonance can be used to evaluate LV filling rates and volumes. Notably, measurements derived by both techniques are affected by LV relaxation and LV filling pressures and are quite similar to measurements and derivatives obtained from mitral inflow velocities.

Tables 1 and 2 summarize the technical aspects, hemodynamic determinants, and clinical applications including limitations of each of the Doppler and 2D parameters.²⁻⁵⁰ Doppler signals that occur at end-diastole correlate best with LVEDP. These include mitral peak A velocity at tips level, A-wave duration at the annulus, A velocity deceleration time (DT), pulmonary vein peak Ar velocity, Ar velocity duration, Ar-A duration, and tissue Doppler-derived mitral annular a' velocity. Mitral peak E-wave velocity, E/A ratio, E velocity DT, E/e' ratio, pulmonary vein systolic-to-diastolic velocity ratio, and peak velocity of tricuspid regurgitation (TR) by continuous-wave (CW) Doppler relate best with earlier occurring LV diastolic pressures (mean PCWP, pre-A pressure, and mean LV diastolic pressure).

I. GENERAL PRINCIPLES FOR ECHOCARDIOGRAPHIC ASSESSMENT OF LV DIASTOLIC FUNCTION

The application of the guidelines starts with taking note of the clinical data, heart rate, blood pressure, 2D and Doppler findings with respect to LV volumes/wall thickness, ejection fraction (EF), LA volume, presence and severity of mitral valve disease as well as the underlying rhythm. The guidelines are not necessarily applicable to children or in the perioperative setting. This is an important first step because there may be recommendations that are specific to the underlying pathology. Second, the quality of the Doppler signal as well as the limitations for each parameter should be carefully examined. If a Doppler signal is suboptimal, that signal should not be used in formulating conclusions about LV diastolic function (Figures 2 and 3). Third, the presence of a single measurement that falls within the normal range for a given age group does not necessarily indicate normal diastolic function (see below). Given the several hemodynamic factors that affect each signal, some measurements may fall in the normal range despite the presence of diastolic dysfunction, and none of the indices should be used in isolation. Therefore, consistency between two or more of the indices should be relied upon in an individual patient. The echocardiographic indices of diastolic function

dysfunction. In the majority of clinical studies, LV filling pressures and diastolic function grade can be determined reliably by a few simple echocardiographic parameters with a high feasibility. In addition, technical developments have emerged that provide new indices that appear promising for studying LV diastolic function. This update places more emphasis on applying the most useful,

Download English Version:

<https://daneshyari.com/en/article/5609376>

Download Persian Version:

<https://daneshyari.com/article/5609376>

[Daneshyari.com](https://daneshyari.com)